| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 10
| Issue : 3 | Page : 107-113 |
|
|
Dendritic cell-based immunotherapies and their potential use in colorectal cancer immunotherapy
Alia M Aldahlawi1, Samaa Taha Abdullah2
1 Department of Biological Sciences, Faculty of Science, King Abdulaziz University; Immunology Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
2 Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
Correspondence Address:
Dr. Samaa Taha Abdullah
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589
Saudi Arabia
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jmau.jmau_20_21
|
|
|
Dendritic cells (DCs) are professional antigen-presenting cells, which are resident or proliferating in organs. Major histocompatibility complex (MHC) Class I and II on DCs in normal steady conditions process and present antigens including cancer antigens. Many approaches are used to enhance antigen presentation process of DCs and capture cancer cells. DCs are harvested from cancer patients and manipulated ex vivo in DC-based cancer immunotherapy. In addition, DCs' vaccines and other anticancer therapy combinations were discussed to optimize DCs' efficiency for cancer immunotherapy. This review addressed the use of the human conventional type-1 DCs, OX40+ plasmacytoid DCs, and DCs-derived exosomes. In addition, different combinations with DCs therapy such as combination with the monoclonal antibody, cytokine-induced killer cells, adjuvants, chemotherapy (DCs-based chemoimmunotherapy), and nanoparticles were listed and explored for their effectiveness against cancer, and mainly against colorectal cancer.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
